Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.

NCT02614521 is registered in ClinicalTrials.gov with Elpen Pharmaceutical Co. Inc. as lead sponsor.

NCT NCT02614521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02614521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.
Lead sponsor
Elpen Pharmaceutical Co. Inc.
Phase
Observational
Overall status
Withdrawn
Start date
January 31, 2017
Completion date
February 28, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation